Drug safety assessment in clinical trials: methodological challenges and opportunities
暂无分享,去创建一个
[1] C. Furberg,et al. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.
[2] Sonal Singh,et al. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies , 2011, BMJ : British Medical Journal.
[3] Su Golder,et al. Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview , 2011, PLoS medicine.
[4] C. Furberg,et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.
[5] C. Granger,et al. Do we need to adjudicate major clinical events? , 2008, Clinical trials.
[6] Galit Shmueli,et al. Fundamentals of Clinical Trials, 4th edition , 2012 .
[7] J. Prochaska,et al. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.
[8] S. Golder,et al. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources , 2011, Therapeutic advances in drug safety.
[9] J. Aronson,et al. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. , 2004, British journal of clinical pharmacology.
[10] Mark S Levenson,et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration , 2009, BMJ : British Medical Journal.
[11] C. Furberg,et al. The FDA and new safety warnings. , 2012, Archives of internal medicine.
[12] C. Furberg,et al. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.
[13] J. Maurer. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials , 2012 .
[14] J. Nunnelee. Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572. , 2008 .
[15] Guosheng Yin,et al. Fundamentals of Clinical Trials , 2012 .
[16] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[17] M. Harrison‐Woolrych,et al. Cardiovascular Events in Patients taking Varenicline , 2012, Drug Safety.
[18] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[19] M. Viswanathan,et al. Assessing equivalence and noninferiority. , 2012, Journal of clinical epidemiology.
[20] Peter W Lane,et al. Meta-analysis of incidence of rare events , 2013, Statistical methods in medical research.
[21] Yoon K Loke,et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.
[22] Kay Dickersin,et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. , 2009, The New England journal of medicine.
[23] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[24] Alexander J Sutton,et al. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.
[25] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[26] Jonathan J Deeks,et al. Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events , 2007, Statistics in medicine.
[27] Curt D. Furberg,et al. Suicidal Behavior and Depression in Smoking Cessation Treatments , 2011, PloS one.
[28] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .
[29] J. Woodcock,et al. New FDA regulation to improve safety reporting in clinical trials. , 2011, The New England journal of medicine.
[30] Christine M. Micheel,et al. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .
[31] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[32] Yoon K Loke,et al. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. , 2009, Archives of internal medicine.
[33] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[34] Y. Loke,et al. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis , 2000, BMJ : British Medical Journal.
[35] G. Guyatt,et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. , 2011, QJM : monthly journal of the Association of Physicians.
[36] S. Schinner,et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[37] Amy T. Wang,et al. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review , 2010, BMJ : British Medical Journal.
[38] LJ Lesko,et al. Pharmacological Mechanism‐Based Drug Safety Assessment and Prediction , 2011, Clinical pharmacology and therapeutics.
[39] R. Ferner. Newly licensed drugs , 1996, BMJ.
[40] Nicholas C. Ide,et al. The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.
[41] P. Enright,et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications , 2012, Thorax.
[42] Sonal Singh,et al. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update , 2010, Current opinion in pulmonary medicine.
[43] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[44] T. Hammad,et al. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations , 2011, Clinical trials.
[45] Janet Woodcock,et al. Role of postmarketing surveillance in contemporary medicine. , 2011, Annual review of medicine.
[46] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[47] Y. Loke,et al. Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel , 2012, Drug Safety.
[48] Tianjing Li,et al. Network meta-analysis-highly attractive but more methodological research is needed , 2011, BMC medicine.
[49] C. Furberg,et al. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis , 2011, Thorax.
[50] N. Rigotti,et al. Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial , 2010, Circulation.